Published in Menopause on November 10, 2008
Cognitive response to estradiol in postmenopausal women is modified by high cortisol. Neurobiol Aging (2011) 0.79
The effect of hormone therapy on surrogate measures of cardiovascular disease: lessons learned. Menopause (2008) 0.75
The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril (2008) 5.31
Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab (2006) 4.56
The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod (2009) 3.74
Urinary incontinence in young nulligravid women: a cross-sectional analysis. Ann Intern Med (2012) 3.34
Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med (2008) 3.25
Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril (2011) 2.80
Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism. J Clin Endocrinol Metab (2003) 2.59
Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab (2010) 2.48
Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ (2003) 2.40
Circulating androgen levels and self-reported sexual function in women. JAMA (2005) 2.40
Adjuvant therapy, not mammographic screening, accounts for most of the observed breast cancer specific mortality reductions in Australian women since the national screening program began in 1991. Breast Cancer Res Treat (2011) 2.18
Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: a randomized, placebo-controlled trial. Menopause (2006) 2.07
Incidence of total knee and hip replacement for osteoarthritis in relation to circulating sex steroid hormone concentrations in women. Arthritis Rheumatol (2014) 2.05
Glucose tolerance abnormalities in Australian women with polycystic ovary syndrome. Med J Aust (2007) 2.03
Sexual function after breast cancer. J Sex Med (2010) 1.89
Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update (2010) 1.86
Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin. Clin Chem (2009) 1.82
Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update (2013) 1.81
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev (2012) 1.76
Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. Menopause (2015) 1.71
Endogenous androgen levels and cardiovascular risk profile in women across the adult life span. Menopause (2007) 1.70
The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J Clin Endocrinol Metab (2012) 1.47
Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev (2011) 1.47
Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis. Menopause (2014) 1.46
Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril (2008) 1.44
Power Doppler assessment of follicle vascularity at the time of oocyte retrieval in in vitro fertilization cycles. Fertil Steril (2008) 1.44
The incidence of invasive breast cancer among women prescribed testosterone for low libido. J Sex Med (2009) 1.42
Obesity increases the risk of spontaneous abortion during infertility treatment. Obes Res (2002) 1.42
Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reverses the adverse effects of diet-induced obesity on oocyte quality. Endocrinology (2008) 1.41
Obese women exhibit differences in ovarian metabolites, hormones, and gene expression compared with moderate-weight women. J Clin Endocrinol Metab (2009) 1.40
Low use of effective and safe therapies for moderate to severe menopausal symptoms: a cross-sectional community study of Australian women. Menopause (2016) 1.38
Macrophage contributions to ovarian function. Hum Reprod Update (2004) 1.35
Beta-oxidation is essential for mouse oocyte developmental competence and early embryo development. Biol Reprod (2010) 1.34
Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril (2008) 1.30
Influence of acupuncture stimulation on pregnancy rates for women undergoing embryo transfer. Fertil Steril (2006) 1.30
High-fat diet causes lipotoxicity responses in cumulus-oocyte complexes and decreased fertilization rates. Endocrinology (2010) 1.29
The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome. J Clin Endocrinol Metab (2008) 1.29
Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med J Aust (2011) 1.23
Obesity and menstrual irregularity: associations with SHBG, testosterone, and insulin. Obesity (Silver Spring) (2009) 1.22
Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev (2011) 1.22
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev (2010) 1.21
Preconception lifestyle advice for people with subfertility. Cochrane Database Syst Rev (2010) 1.16
Dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in women. J Clin Endocrinol Metab (2007) 1.14
Programming and reproductive functioning. Trends Endocrinol Metab (2002) 1.14
Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Lancet (2002) 1.11
Insulin resistance increases the risk of spontaneous abortion after assisted reproduction technology treatment. J Clin Endocrinol Metab (2007) 1.10
Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. Fertil Steril (2009) 1.08
Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis (2005) 1.07
Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab (2009) 1.07
Impact of obesity on female fertility and fertility treatment. Womens Health (Lond Engl) (2008) 1.07
Prevalence and incidence of urinary incontinence in women: review of the literature and investigation of methodological issues. Int J Urol (2008) 1.06
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev (2009) 1.06
Sexual function in well women: stratification by sexual satisfaction, hormone use, and menopause status. J Sex Med (2008) 1.05
Letter to the editor: Randolph J, et al. Masturbation frequency and sexual function domains are associated with serum reproductive hormone levels across the menopausal transition. J Clin Endocrinol Metab (2015) 1.05
Knowledge about factors that influence fertility among Australians of reproductive age: a population-based survey. Fertil Steril (2012) 1.05
Aromatase inhibitors for PCOS: a systematic review and meta-analysis. Hum Reprod Update (2012) 1.04
Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. Lancet Oncol (2005) 1.03
Incidence of spontaneous abortion among pregnancies produced by assisted reproductive technology. Hum Reprod (2004) 1.02
Short-term meal replacements followed by dietary macronutrient restriction enhance weight loss in polycystic ovary syndrome. Am J Clin Nutr (2006) 1.02
Single embryo transfer reduces the risk of perinatal mortality, a population study. Hum Reprod (2012) 1.01
Implanon users are less likely to be satisfied with their contraception after 6 months than IUD users. Contraception (2009) 1.01
Age-specific prevalence of, and factors associated with, different types of urinary incontinence in community-dwelling Australian women assessed with a validated questionnaire. Maturitas (2009) 1.00
Androgens and polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes (2009) 0.99
Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med (2005) 0.98
Total cholesterol and triglycerides are associated with the development of new bone marrow lesions in asymptomatic middle-aged women - a prospective cohort study. Arthritis Res Ther (2009) 0.98
Increased beta-oxidation and improved oocyte developmental competence in response to l-carnitine during ovarian in vitro follicle development in mice. Biol Reprod (2011) 0.98
Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis (2008) 0.98
Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril (2010) 0.98
C-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome. J Clin Endocrinol Metab (2007) 0.98
The longer-term health outcomes for children born as a result of IVF treatment. Part II--Mental health and development outcomes. Hum Reprod Update (2013) 0.97
Genetic and gene expression analyses of the polycystic ovary syndrome candidate gene fibrillin-3 and other fibrillin family members in human ovaries. Mol Hum Reprod (2009) 0.96
Sexual function, incontinence, and wellbeing in women after rectal cancer--a review of the evidence. J Sex Med (2012) 0.95
The longer-term health outcomes for children born as a result of IVF treatment: Part I--General health outcomes. Hum Reprod Update (2013) 0.95
Exposure to lipid-rich follicular fluid is associated with endoplasmic reticulum stress and impaired oocyte maturation in cumulus-oocyte complexes. Fertil Steril (2012) 0.94
The erectile-endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention. Nat Clin Pract Cardiovasc Med (2007) 0.93
Urinary incontinence is associated with lower psychological general well-being in community-dwelling women. Menopause (2010) 0.93
What do obstetricians think about media influences on their patients? Aust N Z J Obstet Gynaecol (2006) 0.92
Infertility caused by HCG autoantibody. J Clin Endocrinol Metab (2002) 0.92
Effects of lifestyle modification in polycystic ovarian syndrome. Reprod Biomed Online (2006) 0.92
Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial. J Clin Endocrinol Metab (2006) 0.92
Expression of leptin and its receptor in the murine ovary: possible role in the regulation of oocyte maturation. Biol Reprod (2002) 0.92
Polymorphism in HSD17B6 is associated with key features of polycystic ovary syndrome. Fertil Steril (2006) 0.91
Polycystic ovarian syndrome: marked differences between endocrinologists and gynaecologists in diagnosis and management. Clin Endocrinol (Oxf) (2005) 0.91
Endoplasmic reticulum (ER) stress in cumulus-oocyte complexes impairs pentraxin-3 secretion, mitochondrial membrane potential (DeltaPsi m), and embryo development. Mol Endocrinol (2012) 0.90
Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia. Med J Aust (2012) 0.90
High sensitivity C-reactive protein is associated with lower tibial cartilage volume but not lower patella cartilage volume in healthy women at mid-life. Arthritis Res Ther (2008) 0.89
Factors identified during the neonatal period associated with risk of cerebral palsy. Aust N Z J Obstet Gynaecol (2004) 0.89
Postprandial ghrelin, cholecystokinin, peptide YY, and appetite before and after weight loss in overweight women with and without polycystic ovary syndrome. Am J Clin Nutr (2007) 0.89
Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care (2008) 0.88
Single or multiple embryo transfer following in vitro fertilisation for improved neonatal outcome: a systematic review of the literature. Aust N Z J Obstet Gynaecol (2004) 0.88
Soluble adhesion molecules in serum throughout the menstrual cycle. Hum Reprod (2002) 0.87
Extent of metabolic risk in adolescent girls with features of polycystic ovary syndrome. Fertil Steril (2011) 0.87
Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod (2008) 0.86
Negative beliefs about low back pain are associated with high pain intensity and high level disability in community-based women. BMC Musculoskelet Disord (2008) 0.86
Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. Arch Intern Med (2003) 0.86